Up to 78% of patients treated with TOPO experience severe neutropenia [18], often requiring interventions like granulocyte colony-stimulating factor (G-CSF) and, in many cases, red blood cell transfusions due to anemia. This evidence concerns the gene CSF3 and Decreased total neutrophil count.